Cover image not available

Costing statement : Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70) : Implementing NICE guid

National Institute for Health and Clinical Excellence

Publication Data

Title Costing statement : Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70) : Implementing NICE guid
Alternative Title Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70)
Author National Institute for Health and Clinical Excellence
Publisher National Institute for Health and Clinical Excellence
Publication date 0000
Publication location London

Descriptive Notes

"Technology appraisal implementation tools."

Topics

Chronic myeloid leukemia :: Chemotherapy :: England :: Cost effectiveness
Protein-tyrosine kinase :: Inhibitors
Imatinib

Catalogue Data

OBNB ID GBB586184
ISBN 10 n/a
ISBN 13 n/a
Type BibliographicResource, Book
Dewey Classification 616.99419061

ISBD

P1053 1 online resource (4 pages).
P1042 Includes bibliographical references.

Buy a copy

OBNB doesn't sell books, but you may be able to find a copy at one of these websites:

Costing statement : Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment of chronic myeloid leukaemia (part review of technology appraisal guidance 70) : Implementing NICE guid by National Institute for Health and Clinical Excellence. Published by National Institute for Health and Clinical Excellence. Publication and catalogue information, links to buy online and reader comments.